Economy20 November 20264 min read
PMBJP expands to 20,547 Kendras as awareness and supply gaps persist
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) had 20,547 Jan Aushadhi Kendras operational as of July 2026, compared with an estimated 12 lakh chemist and druggist outlets across India.
The scheme offers generic medicines at prices generally 50–80% below those of comparable branded medicines. Gaps in public awareness, prescribing, medicine availability and confidence in quality continue to constrain its reach and use.
How PMBJP supplies affordable generic medicines
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) aims to provide quality-assured generic medicines at affordable prices. It began as the Jan Aushadhi Scheme in 2008 and was revamped in 2015. The Pharmaceuticals and Medical Devices Bureau of India (PMBI) implements it under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers.
The scheme’s main features include:
- Medicines and products: Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) offer 2,110 medicines and 315 surgical products, medical devices and consumables across 29 therapeutic categories. These include treatments for diabetes, cardiovascular diseases, cancer and infectious diseases.
- Quality checks: Medicines are procured from WHO-GMP-compliant manufacturers and undergo batch-wise testing in NABL-accredited laboratories before distribution.
- Kendra operations: The franchise-based model provides operators a 20% trade margin and performance-linked incentives of up to ₹5 lakh. Eligible women, SC/ST and Divyangjan entrepreneurs, and Kendras in designated underserved regions, can receive an additional one-time incentive of up to ₹2 lakh.
- Finding medicines and outlets: The Jan Aushadhi Sugam App supports medicine searches, price comparisons and identification of nearby Kendras. Primary Agricultural Credit Societies (PACS), government hospitals and railway stations are also being used to expand access, particularly in rural and underserved areas.
- Related initiatives: Jan Aushadhi Suvidha, introduced in 2019, provides subsidised sanitary napkins at ₹1 per pad. Jan Aushadhi Diwas is observed annually on 7 March to raise awareness about affordable, quality-assured generic medicines.
How the Kendra network and reported savings have grown
The network grew from 17,990 Kendras in December 2025 to 20,547 by July 2026. The government aims to have 25,000 Kendras by March 2027.
| Measure | Figure |
|---|---|
| Kendras in December 2025 | 17,990 |
| Kendras in July 2026 | 20,547 |
| Government target by March 2027 | 25,000 |
| Estimated chemist and druggist outlets | About 12 lakh |
| Kendras as a share of estimated outlets | About 1.7% |
| Sales at MRP in FY 2025–26 | ₹2,252 crore |
| Government-estimated savings in FY 2025–26 | About ₹9,000 crore |
| Government-estimated savings over 12 years | ₹45,000 crore |
Sales at MRP reached ₹2,252 crore in FY 2025–26, while the government estimated savings of about ₹9,000 crore for the year. Medicines sold through Kendras are generally 50–80% cheaper than comparable branded alternatives.
What limits awareness, prescribing and confidence in the scheme
A study of 200 outpatients in Port Blair found that only one-third knew about the scheme, while 6% had asked doctors for generic medicines. The findings are not nationally representative.
Patients largely depend on doctors’ prescriptions. A generic-prescription directive issued by the National Medical Commission was put on hold after objections concerning professional autonomy, accountability and medicine quality.
Quality concerns and medicine availability also affect confidence in the scheme:
- Substandard medicine rates were reported at 0.34% under PMBJP and 3.70% in the open market. Transparent, comparable testing data are needed before firm conclusions can be drawn from the figures.
- Stock shortages and irregular availability of prescribed medicines persist despite an IT-enabled supply-chain management system. These problems can discourage repeat visits and weaken public confidence.
How medicine costs fit into wider public health coverage
Government health expenditure stood at 1.43% of GDP in 2023–24, against the National Health Policy, 2017 target of 2.5% by 2025. PMBJP provides affordable medicines as part of the response to treatment costs, but outpatient medicine expenses remain largely outside the hospitalisation-focused coverage of the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY).